EMA's CHMP recommends Tesaro's Zejula for ovarian cancer

EMA’S CHMP recommended approval of Zejula niraparib (MK-4827, ZL-2306) from Tesaro Inc. (NASDAQ:TSRO) as monotherapy for the maintenance treatment of adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy...